A new over-the-counter option for red eyes has been approved. On October 16, 2026, the FDA approved Brytly (apraclonidine ophthalmic solution 0.125%, made by Alcon) as a nonprescription eye drop for relief of eye redness caused by minor irritations. It is the first nonprescription eye drop containing apraclonidine (FDA).
Apraclonidine itself is not new. Eye drops with higher concentrations of the drug are available by prescription to lower eye pressure in people with glaucoma and before or after certain laser treatments of the eye. What changes is that a low-strength version is now approved for nonprescription use against everyday redness.
Who can use it
Adults and children 12 years and older
How often
No more than twice a day
Contact lenses
Remove first; wait at least 10 minutes before reinserting
When to stop
Eye pain, vision changes, or redness lasting more than 3 days
Source: FDA statement, October 16, 2026.
What causes the redness it treats
According to the FDA, eye redness is most often caused by swollen or dilated blood vessels on the surface of the eye, which can be triggered by minor irritations such as dryness or dust. Brytly is meant for that kind of temporary redness, not for treating an underlying eye disease. Apraclonidine joins brimonidine, the ingredient in Lumify, which has been sold over the counter for eye redness since 2017 (Healio).
How to use it safely
The FDA advises reading the full Drug Facts label before use. Brytly should not be used more than two times a day. Contact lenses should be taken out before applying the drops and put back in no sooner than 10 minutes later, and people using other eye drops should wait 5 minutes between products (FDA).
When red eyes need a doctor instead
An over-the-counter drop is for minor, temporary irritation. The FDA says to stop using Brytly and ask a doctor if you have eye pain, changes in vision, continued redness or irritation, or if the problem lasts more than three days or gets worse. The FDA announcement does not include clinical trial results, so it does not show how Brytly compares with other nonprescription redness relievers.
What it means for consumers
For people who occasionally reach for redness-relief drops, the approval adds another ingredient to choose from at the pharmacy. It does not change the basic rule for red eyes: persistent redness, pain or changes in vision are a reason to see a doctor, not to keep using drops. Children under 12 should not use Brytly.
The takeaway
The FDA has approved Brytly (apraclonidine 0.125%) as the first nonprescription apraclonidine eye drop for redness from minor irritation, for ages 12 and up, used no more than twice a day. Stop using it and see a doctor for eye pain, vision changes, or redness that lasts more than three days.